Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo
about
Advance of molecular imaging technology and targeted imaging agent in imaging and therapyTargeted nanotechnology for cancer imaging.Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targetingThe short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism.PSMA-targeted theranostic nanoplex for prostate cancer therapy.Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon.Nanotechnology for energy-based cancer therapiesOptimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system.Multifunctional, stimuli-sensitive nanoparticulate systems for drug deliveryIncorporation of paramagnetic, fluorescent and PET/SPECT contrast agents into liposomes for multimodal imagingTheranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives.Lipid-based nanoparticles in cancer diagnosis and therapy.Tumor specific delivery and therapy mediate by integrin β6-target immunoliposomes for β6-siRNA in colon carcinoma.Advanced methodologies to formulate nanotheragnostic agents for combined drug delivery and imaging.In vivo imaging of the systemic delivery of small interfering RNA.Nanocarrier systems for delivery of siRNA to ovarian cancer tissues.Nanotechnology based platforms for survivin targeted drug discovery.Targeted nanotheranostics for personalized cancer therapy.Multimodality imaging of RNA interferenceLiposomes in drug delivery: a patent review (2007 - present).Delivery of RNAi therapeutics: work in progress.Theranostic nanoparticles for cancer and cardiovascular applications.Delivering the promise of small ncRNA therapeutics.Cancer immunotherapy: nanodelivery approaches for immune cell targeting and trackingImage-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles.Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA.Nanomedicines for renal disease: current status and future applicationsOligonucleotide-based theranostic nanoparticles in cancer therapy.Nanomedicine therapeutics and diagnostics are the goal.Post-coupling strategy enables true receptor-targeted nanoparticles.Advances in siRNA delivery in cancer therapy.Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines.Cationic Lipid-Based Nucleic Acid Vectors.Cationic lipid-based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effectsReprogramming of hepatic fat accumulation and 'browning' of adipose tissue by the short-chain fatty acid acetate.
P2860
Q26851887-AECCB778-96FC-4DCC-9F96-AE784C18B6F4Q27010317-CB89806D-6478-4374-9459-7A475CABB84CQ30456053-42F7A0C1-07D6-4424-9E0C-6C19862FFB8DQ33587361-C981FE24-AA9C-4233-8A18-437D436A224DQ33791366-1F213E4B-4BFA-4AFE-8619-E188ECDCE3D3Q35227495-845E5D5C-72CD-4A3C-8AF1-CD1461A2AA06Q35264028-3B722837-D8C6-48EF-9AFA-F81BF510DBB8Q35676118-5003EA0C-185E-4EBA-9D83-F0B8690FDCAAQ35809872-82AE94E6-91FB-4FB5-9D7C-D38AF52A03A6Q36460517-2E0E838B-C18F-490A-86BE-F23B6232C951Q36777292-48E2FBD0-E67A-4362-A0E4-846F059BD120Q37052002-CA6958BD-0D2D-45DB-AC21-9866BDCCB670Q37709107-E091C76C-7DFC-44DC-8D9C-3D1E0C547B50Q37957956-C3B8018A-D599-41EE-A253-11D44BEB4355Q37974175-257E356D-14D7-4295-A7EF-6DCCA58AD2D2Q38015511-CA3BE124-C1DE-493C-834A-6F3A366B3C46Q38040859-1E8ACEAC-7DAC-4343-8E18-17070C630F0BQ38054793-FDF04E6F-EBF1-41E8-824A-91F402BEDAC8Q38112726-82B67044-BECD-435E-A867-51EA75B8EAC7Q38129924-633C7A5B-E1A5-42CC-9D04-523C92F45074Q38160246-79D6CFED-1DE9-449D-8934-325C5ECF44DCQ38193333-AAB1AAF9-37F3-4770-9D52-F3FCA2A91F29Q38226666-2B2776EB-01EE-47EC-86AC-A49608B44501Q38288055-96F7D117-D5D8-4B67-9E2A-B77A74557423Q38334528-D41F2932-B606-4705-A387-4932423BB668Q38709816-64F120D7-45E4-41DE-B05B-25CF5C8D9D99Q38802375-56E0912F-20D0-4155-91E2-864D8C2C0FADQ38814327-B3254990-EB87-492C-A43E-3C9FA02ED29EQ38842812-D2B607CF-10BC-4D60-8C0A-08F6EE6D63C0Q38988894-E54A65CC-BBC7-4012-99C4-FDE8115FF766Q39250878-FF69E7BA-07E3-48A8-8F73-DD9A1BAD6DC6Q39509073-2913BDC5-8854-4272-A6E9-77B4AD7F1286Q40642464-A433A15B-785B-41C5-AE8F-47D4238EB484Q41089533-23C1D34C-566D-4E5B-9548-65338492B8B5Q52880767-2FA7AFD0-50F5-494E-862C-69E3B2D11FFF
P2860
Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo
description
im Januar 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 October 2010
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2011
@uk
name
Novel multifunctional nanopart ...... eutic tumour reduction in vivo
@en
Novel multifunctional nanopart ...... eutic tumour reduction in vivo
@nl
type
label
Novel multifunctional nanopart ...... eutic tumour reduction in vivo
@en
Novel multifunctional nanopart ...... eutic tumour reduction in vivo
@nl
prefLabel
Novel multifunctional nanopart ...... eutic tumour reduction in vivo
@en
Novel multifunctional nanopart ...... eutic tumour reduction in vivo
@nl
P2093
P1476
Novel multifunctional nanopart ...... eutic tumour reduction in vivo
@en
P2093
Andrew D Miller
Elham Shamsaei
Gavin D Kenny
Jimmy D Bell
Leigh P Brody
Meliz Sahuri
P304
P356
10.1016/J.JCONREL.2010.09.020
P407
P577
2010-10-01T00:00:00Z